Schizophrenia Bulletin Advance Access originally published online on January 22, 2008
Schizophrenia Bulletin 2008 34(2):258; doi:10.1093/schbul/sbm162
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.
Issues in Psychopharmacology
2 The Zucker Hillside Hospital Glen Oaks, New York, NY
3 Technischen Universitat Muenchen, Muenchen, Germany
| The first 10% of the full text of this article appears below. |
Although pharmacologic treatment remains a critical element in the short- and long-term management of schizophrenia, the past decade has been a challenging time in terms of real progress. Despite the introduction of several new medications as well as the conduct of larger and more diverse clinical trials, there remains considerable debate as to how far
1 To whom correspondence should be addressed; e-mail: psychiatry@lij.edu.